McNeil Recalls Motrin Drops After Plastic is Found in Ingredient - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

McNeil Recalls Motrin Drops After Plastic is Found in Ingredient


McNeil Consumer Healthcare Division of McNeil-PPC announced on Sept. 6 a voluntary recall at the retail level of three lots of Concentrated Motrin Infants’ Drops Original Berry Flavor (0.5 fl oz bottles) after 1 mm plastic particles were identified in a different product lot during manufacturing.  The lot in which the particles were discovered was not released to the market.

In a press statement posted on www.FDA.gov and the McNeil website, the company reported that the particles originated in a shipment from a third-party supplier of ibuprofen, the active ingredient in the recalled product.  The company said that, out of an abundance of caution, it was recalling the three lots—approximately 200,000 bottles distributed in the United States—that were made with the same batch of active ingredient.  

The company says it has worked with the third party to ensure that corrective measures are currently in place and the potential for adverse medical events related to the reason for this recall is not likely.   

McNeil is asking retailers to remove the affected lots from store shelves and is asking consumers to stop using and dispose of any product they may have that is included in this recall.

Sources: FDA and McNeil Consumer Healthcare Division of McNeil-PPC

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here